2888. Safety and Immunogenicity of an Adjuvanted Chikungunya Virus (CHIKV) Virus-like Particle (VLP) Based Vaccine in Two Pivotal Phase 3 Trials, ≥12 Years of Age

BACKGROUND: CHIKV remains a significant public health concern globally. We report the results of two phase 3 trials evaluating an aluminum hydroxide adjuvanted CHIKV VLP vaccine. METHODS: Two multicenter, randomized, double-blind, placebo-controlled, parallel-group trials were conducted: an adult/ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Jason S, Anderson, Debbie, Mendy, Jason, Muhammad, Sufia, Tindale, Lauren, Loreth, Tobi, Tredo, Sarah Royalty, Jenkins, Victoria, Ajiboye, Patrick, Bedell, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677554/
http://dx.doi.org/10.1093/ofid/ofad500.2471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677554/
http://dx.doi.org/10.1093/ofid/ofad500.2471

Ejemplares similares